Brief: Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial
04/03/2025 13:22
March 4 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES FILES INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA FOR ALS PHASE 2 CLINICAL TRIAL Source text: ID:nGNX4JkHLT Further company coverage: TLSA.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis